As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.
This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology.
